SUDHIR MANDA MD NPI 1164630679

NPI Details

Sudhir Manda, MD is a hematology and oncology internal medicine in Tucson, AZ with 23 years of experience. The provider is an internist doctor of osteopathy that specializes in the treatment of the combination of hematology and oncology disorders. A doctor of osteopathy that is board eligible/certified by the American Osteopathic Board of Internal Medicine WAS able to obtain a Certificate of Special Qualifications in the field of Hematology and Oncology. The Certificate is NO longer offered. Sudhir Manda, MD NPI is 1164630679. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a male.

The provider's business location address is:

603 N WILMOT RD
STE. # 151
TUCSON, AZ
ZIP 85711-701
Phone: (520) 886-0206
Fax: (520) 886-0829

The NPI 1164630679 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram (HCPCS:Q5101)
• Injection, darbepoetin alfa, 1 microgram (non-esrd use) (HCPCS:J0881)
• Injection, pembrolizumab, 1 mg (HCPCS:J9271)
• Injection, daratumumab, 10 mg and hyaluronidase-fihj (HCPCS:J9144)
• Injection, fosaprepitant, 1 mg (HCPCS:J1453)
• Injection, paclitaxel, 1 mg (HCPCS:J9267)
• Injection, aprepitant, 1 mg (HCPCS:J0185)
• Injection, denosumab, 1 mg (HCPCS:J0897)
• Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg (HCPCS:Q5119)
• Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
• Injection, granisetron hydrochloride, 100 mcg (HCPCS:J1626)
• Injection, palonosetron hcl, 25 mcg (HCPCS:J2469)
• Injection, fulvestrant, 25 mg (HCPCS:J9395)
• Injection of additional new drug or substance into vein (HCPCS:96375)
• Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
• Established patient office or other outpatient visit, 40-54 minutes (HCPCS:99215)
• Injection, fluorouracil, 500 mg (HCPCS:J9190)
• Injection, carboplatin, 50 mg (HCPCS:J9045)
• Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a (HCPCS:G9678)
• Injection of drug or substance under skin or into muscle (HCPCS:96372)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Collection of blood sample from implanted device (HCPCS:36591)
• Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg (HCPCS:J9201)
• Injection, zoledronic acid, 1 mg (HCPCS:J3489)
• Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96401)
• Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
• Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
• Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
• Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
• Infusion, normal saline solution , 1000 cc (HCPCS:J7030)
• Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96402)
• Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
• Unclassified drugs (HCPCS:J3490)
• New patient office or other outpatient visit, 45-59 minutes (HCPCS:99204)
• Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg (HCPCS:J3420)
• Leuprolide acetate (for depot suspension), 7.5 mg (HCPCS:J9217)
• New patient office or other outpatient visit, 60-74 minutes (HCPCS:99205)
• Infusion into a vein for therapy, prevention, or diagnosis, each additional hour (HCPCS:96366)
• Injection of drug or substance into vein (HCPCS:96374)
• Infusion into a vein for hydration, each additional hour (HCPCS:96361)
• Administration of additional new drug or substance into vein using push technique (HCPCS:96411)
• Irrigation of implanted venous access drug delivery device (HCPCS:96523)
• Infusion into a vein for hydration, 31-60 minutes (HCPCS:96360)
• Drawing of blood for a medical problem (HCPCS:99195)
• Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion (HCPCS:96368)
• Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l (HCPCS:G0498)
• Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries (HCPCS:A9552)
• Follow-up hospital inpatient care per day, typically 35 minutes (HCPCS:99233)
• Initial hospital inpatient care per day, typically 50 minutes (HCPCS:99222)
• Initial hospital inpatient care per day, typically 70 minutes (HCPCS:99223)
• Nuclear medicine study from skull base to mid-thigh with ct scan (HCPCS:78815)
• Not otherwise classified, antineoplastic drugs (HCPCS:J9999)
• Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)

The enumeration date for this NPI number is 5/18/2007 and was last updated on 3/9/2022.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available:

Other Identifiers

The following information regarding additional identifiers associated to this NPI record includes the other identifier number, identifier type, identifier state and issuer.